Patients with peripheral arterial disease (PAD) constitute a subgroup of high-risk hypertensives, but controlled studies on 24-h blood pressure (BP) and diurnal variation of BP are lacking. This study was performed in order to test the hypothesis that office BP (OBP) may underestimate 24-h BP in PAD patients in comparison to a matched control group. In all, 98 male patients (mean age 68 years) with a history of intermittent claudication and an ankle/brachial index less than 0.9, and 94 controls matched for age but without PAD or ischaemic heart disease performed 24-h recordings of ambulatory BP. A total of 59 patients had a history of hypertension and 69 were on treatment with BP-lowering drugs as compared to 17 and 23 of the control subjects, respectively. Office as well as 24-h systolic BP (SBP) were higher in patients as compared to controls (151 7 22 vs 140 7 20 mmHg, Po0.001 and 142 7 14 vs 133 7 15 mmHg, Po0.001, respectively), but did not differ with regard to diastolic BP. In an analysis of covariance with the continuous factors age, office SBP and the categorical factor antihypertensive treatment, 24-h SBP was higher in PAD patients compared to controls (Po0.05). The difference between office and night SBP was lower in PAD patients with antihypertensive treatment compared to controls (P ¼ 0.01). In conclusion, Male patients with PAD had higher systolic but not diastolic BP than age-matched control subjects. In PAD patients, 24-h SBP was higher than expected from OBP compared to controls. Night SBP was higher only in patients with antihypertensive treatment. In PAD patients, especially when on antihypertensive treatment, the severity of hypertension may be underestimated when based on OBP only.
Introduction
Patients presenting with intermittent claudication (IC) are at a high risk for cardiovascular complications, mainly due to coronary artery disease (CAD). 1, 2 It is of crucial importance in the management of these patients to address and reduce cardiovascular risk factors. Antihypertensive treatment most certainly has a potential for prevention of cardiovascular morbidity and mortality in these patients, especially in the light of the SHEP, STOP and SYST-Eur trials showing a marked beneficial effect in elderly patients. [3] [4] [5] Also, the HOPE study has recently shown that treatment with the ACE inhibitor ramipril in patients with peripheral arterial disease (PAD) can reduce cardiovascular events, 6 although it is under debate how much of this effect is related to blood pressure (BP) reduction. 7, 8 Ambulatory BP (ABP) monitoring improves risk stratification in hypertensive patients beyond that of office BP (OBP) measurements. 9 In a small pilot study, we found an absence of white coat effect in patients with IC, which could potentially lead to an underestimation of 24-h BP in this patient group. 10 Despite the fact that patients with PAD constitute a large subgroup of high-risk hypertensives, there is no controlled study on ABP and 24-h BP variability in this patient group.
The present study was carried out in order to investigate the relation of OBP to ABP, and test the hypothesis that OBP underestimates 24-h BP in male patients with IC in comparison with an ageand sex-matched control group.
Material and methods

Patients
The study patients were recruited among patients referred to the vascular clinics of Karolinska and St Goran Hospitals, Stockholm, Sweden, according to; male sex, age over 45, a history of IC (leg pain at exercise with prompt relieve at rest not explained by another condition) and an ankle to brachial systolic pressure index (ABI) o0.9 by Doppler ultrasonography at rest. Patients with rest pain, previous amputation or other reasons for a reduced walking performance than IC, diabetes mellitus type I and atrial fibrillation were excluded. A history of ischaemic heart disease (IHD) was not an exclusion criterion and patients were included irrespective of the presence of IHD. Referred patients were screened consecutively during the period 1998-2001 and were, if they did not meet the exclusion criteria, asked for informed consent to participate in the study. In some patients, invasive intervention against PAD was undertaken before the study investigations were initiated and, in these patients, an ABI o0.9 was accepted at the time of the study investigation. To confirm the diagnosis of IC, all patients performed a standardised treadmill test using a graded protocol. A total of 99 patients with IC were finally included. In one patient, ABPM was not performed because office SBP was repeatedly higher than 210 mmHg. Thus, 98 patients remained for the final analysis. The median duration of intermittent claudication was 2 years (P25-P75 ¼ 1-10). In all, 27 patients had a history of previous peripheral vascular surgery. No alteration of medication was done prior to the investigations.
Control subjects
Control subjects, matched for sex and day of birth or in a few cases month of birth, were consecutively drawn from a population register of Stockholm County. Potential control subjects were contacted by a letter with a modified ROSE questionnaire, 11 asking questions on symptoms of PAD as well as history of IHD. Eligible subjects were asked to come for a screening visit when a medical history was obtained, and BP, ankle pressure and a 12-lead ECG were performed. The same exclusion criteria applied for patients and controls. Subjects free from symptoms of PAD and with an ABI 40.9, as well as free from any history of IHD and an ECG without pathological Q-waves and/or LBBB, could enter the study if informed consent was given and if they did not meet the other exclusion criteria. In all, 94 control subjects were sampled, and were considered group matched.
Methods
Office blood pressure (OBP)
OBP was recorded by an experienced nurse in both arms with a mercury sphygmomanometer in the supine position after 5 min of rest. The mean of two consecutive readings was calculated. If there was a difference in systolic or diastolic BP between the arms of 410 mmHg, the arm with the highest reading was used when defining OBP; otherwise, the nondominant arm was used. 12 The same arm was used for OBP and ABP measurements.
ABP measurement
ABP values were obtained using a noninvasive oscillometric system (Spacelabs 90207, Spacelabs Inc., Redmond, WA, USA). 13 The device was fitted to the patient by an experienced nurse. Patients were instructed not to restrict their daily activities during the monitoring periods. Before the start of the monitoring period, the automatic readings were crosschecked against manually measured BP by auscultation. The device was fitted to the nondominant arm, unless a difference of 410 mmHg in SBP between the arms was recorded, in which case the arm with the highest pressure was used. BP and heart rate were recorded automatically every 15 min for a 24-h period.
No manual editing of data was carried out in order to not induce bias. Means were calculated for the whole 24-h period, and for day-(0700-2100) and night-time (2400-0600) periods.
Ethical approval
The study was approved by the Ethics committee of the Karolinska Hospital.
Statistics
Results are presented as means and standard deviations unless otherwise stated. Statistical analysis and database management were performed with STATISTICA, version 6, StatSoft, Inc. (2001). Student's t-tests for dependent or independent samples, or a w 2 -test were used when appropriate. Pearson's correlation coefficient g was calculated for linear correlation. Analysis of covariance (ANCO-VA) was used to analyse the effects of PAD, antihypertensive treatment and the interaction between PAD and treatment on BP levels. Age and OBP were entered as covariates in this analysis. A P-value less than 0.05 was considered significant.
Results
Study patients
Characteristics and medication of the study patients and control subjects are shown in Tables 1 and 2 , respectively.
OBP measurements
Office systolic/diastolic BP was 151 7 22/79 7 10 vs 140 7 20/79 7 10 mmHg (Po0.001/n.s.) in patients and controls, respectively. As expected, in a group of patients with generalised atherosclerotic obliterative disease, a difference in BP between the left and right arms was often found. For systolic BP, this difference was 410 mmHg in nine patients and 420 mmHg in three patients. Among control subjects, this difference was 410 mmHg in seven subjects, but did not exceed 20 mmHg in any subject.
ABP measurements
Adequate recordings with 475% of data retrieved were available in all but three subjects, with a median of 96 readings per patient (range 62-103). In 10 subjects with 415% of the BP measurements not retrievable, BP data were reviewed manually. In one patient, no BPs had been retrieved between 2400 and 0800, and, therefore, no night-time BP or nightday ratio could be calculated. In the other subjects, missing data occurred evenly spread throughout the monitoring period, and means for day, night and 24-h BP could be calculated. BP was measured in the dominant arm in seven subjects (three patients and four control subjects). ABP and OBP for the respective groups are shown in Table 3 . Office and Table 4 .
A large proportion of patients had a history of hypertension and/or IHD, and were treated with drugs affecting both BP levels and potentially also BP variability over 24 h. Also, among the control subjects, a smaller proportion was treated with antihypertensive drugs. To adjust for imbalances and to analyse the effects of PAD on BP levels independently, an ANCOVA was performed. The presence/absence of PAD as well as the presence/ absence of medication with BP-lowering drugs were entered in this model as categorical factors. To control for the effects of age, age was entered as a covariate. The night-day ratio of BP and difference between OBP and ABP were analysed. Only systolic BP was analysed. As OBP is strongly related to the OBPÀ ABP difference, both office SBP and age were added as covariates when analysing these variables.
The results of this analysis are shown in Table 5 . The OBPÀ 24-h ABP difference was lower in PAD patients (mean 6.7 mmHg) compared to control subjects (mean 9.9 mmHg, F ¼ 4.1, Po0.05; Table 5 and Figure 2 ). The OBPÀ day ABP difference was lower in PAD patients, but the difference was not significant (F ¼ 3.31, P ¼ 0.067).
Also, the OBP to average night BP difference was analysed. There was a significant interaction between PAD and antihypertensive treatment (F ¼ 4.17, Po0.05; Figures 3 and 4) . PAD patients with antihypertensive treatment had a smaller difference between office and night ABP (mean 16.2 mmHg) than control subjects on such treatment (mean 24.3 mmHg, F ¼ 6.37, P ¼ 0.01), whereas no difference was seen in untreated subjects.
Antihypertensive treatment tended to be associated with a higher night-day ratio of SBP (P ¼ 0.09). There was no significant interaction between PAD and the presence of antihypertensive treatment (P ¼ 0.13; Table 5 ). In a subgroup analysis, PAD patients with antihypertensive treatment had a higher night-day ratio of SBP when compared to untreated patients (0.90 vs 0.85).
Discussion
In this study, we report the first data on ABP monitoring in patients with intermittent claudication compared to a matched control group. Out of 98 patients, 59 had a history of hypertension as reported by the patient, which is somewhat higher than in epidemiological studies in which the prevalence of hypertension in patients with IC is estimated to be 30-50%, 14,15 depending on the criteria for hypertension. Office as well as ambulatory systolic BP were about 10 mmHg higher than in a matched control group, despite the fact that a much higher proportion of PAD patients already received antihypertensive treatment. However, neither office nor ambulatory diastolic BP differed between the groups. Accordingly, PP was higher in patients with PAD compared to control subjects. PP, measured in the office, 16, 17 has been shown to be a strong and independent predictor for cardiovascular morbidity and mortality. Ambulatory PP may even further improve risk stratification beyond both those of office PP as well as 24-h SBP. 
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A large proportion of patients were on antihypertensive treatment and/or on treatment for IHD, and the investigations were performed during medication (Table 2) . Although current treatment may interfere with the results and affect interpretation, it was not possible for ethical reasons to withdraw such therapy. We believe, however, that our results accurately reflect the usual clinical situation in these patients. To overcome the problem of a possible influence of antihypertensive treatment, an ANCOVA was performed, in which the effects of PAD and antihypertensive treatment were analysed as categorical independent factors, and age and OBP were added as covariates.
In PAD patients, mean systolic OBP was 3 mmHg higher the than mean systolic day ABP (Po0.05), but in control subjects systolic OBP and day ABP did not differ significantly. There was no significant difference between PAD patients and control subjects for the OBPÀ day ABP difference in univariate analysis. However, as the OBPÀABP difference is strongly correlated to the level of OBP, OBP was entered as a covariate in an ANCOVA, together with age and the categorical factor of antihypertensive treatment. In this analysis, the difference between systolic OBP and 24-h ABP was significantly smaller in PAD patients than in controls, that is, corrected for the strong influence of a higher office SBP in the PAD group, for a given OBP -PAD patients had a higher 24-h ABP than control subjects.
In most, but not all studies, BP recorded in the clinic is higher than home or daytime ABPs. 9, 19 This difference has been assumed to be due to an alerting reaction to the clinic environment, 'the white coat effect' (WCE). The WCE is usually defined as the difference between OBP and average daytime BP, which was also the definition used in this study. Verdecchia et al 20 reported a WCE of 14/6 mmHg in 1280 untreated hypertensives. 20 This effect has been reported to increase with age 21 and with higher clinical BP levels. The reported difference in WCE in different studies could depend on different methods used when measuring OBP and ABP, but probably also on the selection of study populations. If the studied population is selected on the basis of OBP (i.e. hypertensives), a more pronounced WCE can be expected, and when patients in the upper distribution field of OBP are selected a higher WCE will be found.
In this study, although the prevalence of hypertension was high, patients were selected unbiased of BP and so were control subjects. This might very well explain the findings of our study with an overall relatively small OBPÀ ABP difference compared to other studies. The WCE correlated with the level of OBP in both PAD patients and control subjects ( Table 4 ). The higher the OBP, the higher was the difference between OBP and 24-h or day ABP. In control subjects, the WCE correlated with age but this was not the case in PAD patients.
Although most of the knowledge regarding BP as a risk factor is based on prospective cohort studies on OBP, 22 ABP is a better predictor of cardiovascular risk than OBP. 9, 23 In a small pilot study, we found an absence of a WCE in patients with IC. 10 If patients with IC are characterised by a systematic difference in the relation of OBP À ABP compared to other patient groups, this has important clinical implications. Thus, patients with IC with a given OBP would tend to have a higher ABP than what could be expected in the average patient with the same OBP. This implies an increased cardiovascular risk as well as an increased prevalence of hypertensive end-organ damage compared to the non-PAD patients with the same OBP. A risk assessment based on OBP alone would therefore underestimate cardiovascular risk in patients with IC. In the present Ambulatory BP in PAD P Svensson et al study, this underestimation of ABP in PAD patients compared to controls averaged 3 mmHg for 24-h BP. For PAD patients with antihypertensive treatment, this underestimation was higher and especially so for night SBP. For PAD-patients on antihypertensive treatment, the underestimation of night SBP averaged 8 mmHg compared to controls for a given OBP. Consequently, the cardiovascular risk would be much higher in the PAD patients, not only due to the presence of PAD but also because of a higher ABP, despite the fact that the OBPs are the same.
In average, the patients showed a dip of night-time SBP of 12%, which was somewhat less than in control subjects, but the difference was not significant. In a multivariate analysis, the presence of antihypertensive treatment was associated with a higher night-day ratio of SBP. In a subgroup analysis, this difference was only seen in PAD patients on antihypertensive treatment (who had a higher night-day ratio than patients not treated for hypertension). This finding, as well as the finding of a higher than expected night BP in treated PAD patients, may reflect the fact that for the majority of patients antihypertensive treatment effect is monitored and guided by OBP, that is, day BP. With most, if not all antihypertensive agents, there is a variation of the BP-lowering effect during the 24-h period, with a peak effect some hours after administration and about 30-80% of the maximum effect still present after 24 h. 24 Therefore, night BP may not be lowered to the same extent as day BP in treated hypertensives if the antihypertensive drug is administered in the morning.
The night/day ratio of systolic ABP has in prospective studies been documented as a predictor of cardiovascular events. 23, 25, 26 In a substudy on 393 patients (1666 patient-years) in the placebo arm of the SYST-Eur study, the night/day ratio of ABP, independently of 24-hour BP-levels, showed an inverse association to cardiovascular events during In a meta-analysis of antihypertensive trials, a reduction of OBP reduces the risk for stroke correspondingly to what can be expected from observational studies. 22, 27 For coronary events, however, the relative risk reduction is somewhat less than what would be expected from epidemiological data. 27, 28 An insufficient BP reduction during the entire 24-h period may be one of many possible explanations for this discrepancy. In the HOPE study, in which a significant reduction of cardiovascular events was seen despite a modest reduction in OBP, a marked reduction of night BP was reported in a small substudy on patients with IC. 8 An effect on night and morning BPs by giving antihypertensive treatment at bedtime (such as in HOPE) may be of special importance, considering that cardiovascular events are most frequent during the early morning hours. 29 
Summary
Male patients with PAD had higher office, as well as ambulatory systolic BP and PP, but not diastolic BP as compared to age-matched control subjects. When adjusting for age, systolic OBP and antihypertensive treatment, systolic ABP was higher in PAD patients compared to control subjects for a given systolic OBP. Further, in patients with antihypertensive treatment, this difference was higher and especially so for average night SBP. In PAD patients, especially when under antihypertensive treatment, the severity of hypertension may thus be underestimated when based on office BP only. Ambulatory BP in PAD P Svensson et al
